Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

1.

Effect of endocrine treatment on voiding and prostate size in men with prostate cancer: a long-term prospective study.

Klarskov LL, Klarskov P, Mommsen S, Svolgaard N.

Scand J Urol Nephrol. 2012 Feb;46(1):37-43. doi: 10.3109/00365599.2011.637953. Epub 2011 Dec 12.

PMID:
22150564
[PubMed - indexed for MEDLINE]
2.

Urinary symptom flare following I-125 prostate brachytherapy.

Cesaretti JA, Stone NN, Stock RG.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):1085-92.

PMID:
12829146
[PubMed - indexed for MEDLINE]
3.

The long-term results with delayed-combined androgen blockade therapy in local or locally advanced prostate cancer.

Soga N, Hori Y, Ogura Y, Hayashi N, Sugimura Y.

Jpn J Clin Oncol. 2012 Jun;42(6):534-40. doi: 10.1093/jjco/hys037. Epub 2012 Mar 20.

PMID:
22438406
[PubMed - indexed for MEDLINE]
Free Article
4.

Implementation of high-dose-rate brachytherapy and androgen deprivation in patients with prostate cancer.

Lilleby W, Tafjord G, Raabe NK.

Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):933-9. doi: 10.1016/j.ijrobp.2011.08.028. Epub 2011 Dec 2.

PMID:
22138456
[PubMed - indexed for MEDLINE]
5.

External-beam radiation therapy and high-dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome.

Martínez-Monge R, Moreno M, Ciérvide R, Cambeiro M, Pérez-Gracia JL, Gil-Bazo I, Gaztañaga M, Arbea L, Pascual I, Aristu J.

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e469-76. doi: 10.1016/j.ijrobp.2011.08.002.

PMID:
22284039
[PubMed - indexed for MEDLINE]
6.

Long-term follow-up of a prospective trial of trimodality therapy of weekly paclitaxel, radiation, and androgen deprivation in high-risk prostate cancer with or without prior prostatectomy.

Hussain A, Wu Y, Mirmiran A, DiBiase S, Goloubeva O, Bridges B, Mannuel H, Engstrom C, Dawson N, Amin P, Kwok Y.

Int J Radiat Oncol Biol Phys. 2012 Jan 1;82(1):167-74. doi: 10.1016/j.ijrobp.2010.09.009. Epub 2010 Oct 30.

PMID:
21036487
[PubMed - indexed for MEDLINE]
7.

Intermittent androgen suppression in prostate cancer: an update of the Vancouver experience.

Pether M, Goldenberg SL, Bhagirath K, Gleave M.

Can J Urol. 2003 Apr;10(2):1809-14.

PMID:
12773232
[PubMed - indexed for MEDLINE]
8.

Can combined androgen blockade provide long-term control or possible cure of localized prostate cancer?

Labrie F, Candas B, Gomez JL, Cusan L.

Urology. 2002 Jul;60(1):115-9.

PMID:
12100935
[PubMed - indexed for MEDLINE]
9.

Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.

Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF.

Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):943-55.

PMID:
12605972
[PubMed - indexed for MEDLINE]
10.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
[PubMed - indexed for MEDLINE]
11.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
[PubMed - indexed for MEDLINE]
12.

Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.

Kok ET, Schouten BW, Bohnen AM, Groeneveld FP, Thomas S, Bosch JL.

J Urol. 2009 Feb;181(2):710-6. doi: 10.1016/j.juro.2008.10.025. Epub 2008 Dec 16.

PMID:
19091352
[PubMed - indexed for MEDLINE]
13.

Primary androgen deprivation (AD) followed by active surveillance (AS) for newly diagnosed prostate cancer (PC): A retrospective study.

Scholz MC, Groom MK, Kaddis AJ, Strum SB, Jennrich RI, Bahn DK, Chang PJ, Becker LK, Lam RY.

Prostate. 2013 Jan;73(1):83-8. doi: 10.1002/pros.22543. Epub 2012 Jul 2.

PMID:
22753276
[PubMed - indexed for MEDLINE]
14.

Androgen deprivation-induced changes in prostate anatomy predict urinary morbidity after permanent interstitial brachytherapy.

Hinerman-Mulroy A, Merrick GS, Butler WM, Wallner KE, Allen Z, Adamovich E.

Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1367-82.

PMID:
15275722
[PubMed - indexed for MEDLINE]
15.

Report of a multicenter Canadian phase III randomized trial of 3 months vs. 8 months neoadjuvant androgen deprivation before standard-dose radiotherapy for clinically localized prostate cancer.

Crook J, Ludgate C, Malone S, Lim J, Perry G, Eapen L, Bowen J, Robertson S, Lockwood G.

Int J Radiat Oncol Biol Phys. 2004 Sep 1;60(1):15-23.

PMID:
15337535
[PubMed - indexed for MEDLINE]
16.

Diethylstilboestrol versus bicalutamide in hormone refractory prostate carcinoma: a prospective randomized trial.

Manikandan R, Srirangam SJ, Pearson E, Brown SC, O'Reilly P, Collins GN.

Urol Int. 2005;75(3):217-21.

PMID:
16215308
[PubMed - indexed for MEDLINE]
17.

Relationship between percent positive biopsies and biochemical outcome after permanent interstitial brachytherapy for clinically organ-confined carcinoma of the prostate gland.

Merrick GS, Butler WM, Galbreath RW, Lief JH, Adamovich E.

Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):664-73.

PMID:
11849788
[PubMed - indexed for MEDLINE]
18.

Transrectal high-intensity focused ultrasound for treatment of localized prostate cancer.

Inoue Y, Goto K, Hayashi T, Hayashi M.

Int J Urol. 2011 May;18(5):358-62. doi: 10.1111/j.1442-2042.2011.02739.x. Epub 2011 Mar 30.

PMID:
21449970
[PubMed - indexed for MEDLINE]
19.

Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.

Teh BS, Ayala G, Aguilar L, Mai WY, Timme TL, Vlachaki MT, Miles B, Kadmon D, Wheeler T, Caillouet J, Davis M, Carpenter LS, Lu HH, Chiu JK, Woo SY, Thompson T, Aguilar-Cordova E, Butler EB.

Int J Radiat Oncol Biol Phys. 2004 Apr 1;58(5):1520-9.

PMID:
15050332
[PubMed - indexed for MEDLINE]
20.

Significant associations of prostate-specific antigen nadir and time to prostate-specific antigen nadir with survival in prostate cancer patients treated with androgen-deprivation therapy.

Huang SP, Bao BY, Wu MT, Choueiri TK, Goggins WB, Liu CC, Huang CY, Pu YS, Yu CC, Wu TT, Huang CN, Huang CH, Wu WJ.

Aging Male. 2012 Mar;15(1):34-41. doi: 10.3109/13685538.2011.580398. Epub 2011 May 26.

PMID:
21615239
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk